Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Notable Labs Ltd's Competitiveness

Name: Notable Labs Ltd Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Notable Labs Ltd (NTBL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2024

Competitors Tracked

Publicly traded peers

Peer Group Market Share

100.00 %

Share of combined sales, Q2 2024

Revenue Growth Y/Y

Q2 2024

Net Margin

-260,950.00 %

Q2 2024

Key Findings: Notable Labs Ltd vs Its Competitors

Peer revenue share: Notable Labs Ltd accounted for 100.0% of combined revenue among its tracked peer group.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

NTBL Sales vs. its Competitors, Q2 2024

Notable Labs Ltd generated 100.00 % of the combined sales of its peer group.

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/NTBL/competitors                    

                        https://api.csimarket.com/api/v1/companies/NTBL/relationships                    

                        https://api.csimarket.com/api/v1/companies/NTBL/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Notable Labs Ltd's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Notable Labs Ltd	-	-	-	Yes
High-Confidence Competitors (2)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

NTBL Stock Performance relative to its Competitors

NTBL Competitors (weighted) Percent change over the selected range

Notable Labs Ltd's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(0 of 2)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Notable Labs Ltd	-	-
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (2)	40.4%	63.2%
Similar-Size Competitors (0)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Notable Labs Ltd's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

NTBL Stock Performance relative to High-Confidence Competitors

NTBL High-Confidence Competitors (equal-weighted, 2) Percent change over the selected range

Notable Labs Ltd's Comment on Competition and Industry Peers

Notable faces competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Its product candidates will compete with approved treatments, off-label therapies, and emerging therapies. Although there are no FDA-approved PLK1 inhibitors currently, several are in clinical development, including Onvansertib by Cardiff Oncology, Inc., GSK461364 by GSK, plc, and rigosertib by Onco. Smaller or early-stage oncology-focused therapeutics companies may also be competitors, particularly through collaborations with larger firms. Competition extends to recruiting personnel, establishing clinical trial sites, enrolling patients, and acquiring complementary technologies. Reimbursement availability from government and private payors will affect the pricing and competitiveness of Notable's products.

Notable Labs Ltd's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Cardiff Oncology, Inc.	Named by the company	85%	2022 to 2026	3
GSK, plc	Named by the company	85%	2022 to 2026	3
Onco	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Notable Labs Ltd's named competitors require a Commercial License.